Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Alabama: - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
- The University of Alabama at Birmingham — Birmingham, Alabama
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Alabama: - Investigative Site US058 — Birmingham, Alabama
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Alabama: - The University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Alabama: - Ohio State University-Telemedicine — Birmingham, Alabama
- Ohio State University-Telemedicine — Mobile, Alabama
- Ohio State University Telemedicine — Montgomery, Alabama
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Alabama: - UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Phase 1 Recruiting Industry
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05208762
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
- University of Alabama at Birmingham, IDS Pharmacy — Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety, dosimetry and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally adva…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06562192
Sites in Alabama: - Uni of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and ate…
Sponsor: ProDa BioTech, LLC
NCT ID: NCT06182072
Sites in Alabama: - O'Neal Comprehensive Cancer Center, University of Alabama — Birmingham, Alabama
Recruiting Network
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as iden…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04239573
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Alabama: - Massive Bio SYNERGY-AI site — Birmingham, Alabama
- Massive Bio SYNERGY-AI site — Mobile, Alabama
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Alabama: - Research Site — Birmingham, Alabama
NA Recruiting Industry
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medical…
Sponsor: Varian, a Siemens Healthineers Company
NCT ID: NCT05764720
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama